Brave River Science Charitable Foundation seeks to expand the modalities and technologies used for Neurofibromatosis Type 1 (NF1) therapies, focusing on those that are disease-modifying, kill tumor cells, or prevent symptom progression.

We prioritize therapeutics that address the root cause of NF1, but when necessary, our primary symptomatic focus is on orthopedic manifestations, cutaneous neurofibromas, and neurocognitive issues.

Our leadership is seasoned biotech, technology, and business professionals. We take an outcome-oriented approach to partnering with academics and biotechs and are laser focused on clinical translation.